Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2018
Price : $35 *
At a glance
- Drugs Lactobacillus reuteri (Primary)
- Indications Acute enterocolitis; Gastrointestinal disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Dec 2018 Results published in the Pediatric Infectious Disease Journal
- 12 Aug 2016 Status changed from not yet recruiting to completed.
- 20 Nov 2014 According to ClinicalTrial.gov record, planned primary completion date changed from 1 Aug 2014 to 1 Jun 2015.